Page 42 - CIBERES2016-ENG

leaD researcher
Blanch Torra, Lluis
corp . sanitaria Parc taulí
Parc Taulí, s/n 08208 Sabadell
(+34) 93 723 10 10 ext. 22229 [email protected]
group website
GROUP MEMBERS
Staff members: Bringue Roque, Josep | Broceño Corrales, Cristina | Magrans Nicieza, Rudys | Turon Viñas, Marc Associated members: Artigas Raventos, Antonio | Fernández Fernández, Rafael | Ferrer Roca, Ricard | López Aguilar, Josefina | Martín Loeches Carrondo, Ignacio Esteban | Martínez Pérez, Melcior | Ochagavia Calvo, Ana | Valles Daunis, Jorge
Main lines of research
The main research lines of our group combine preclinical and clinical studies from a translational perspective and are integrated into two main programs: 1) Diffused Respiratory Diseases, including projects related to Acute Lung Injury and 2) Respiratory Infectious Diseases: which includes Translational Multidisciplinary Research in Respiratory Tract Infections.
We are interested in the diagnosis and characterization of molecular, cellular and physiological changes related to the development of acute lung injury and respiratory infections, as well as the impact on other organs or systems and the development of new therapeutic strategies.
• Management and monitoring of critically ill patients:
ARDS/ALI, mechanical ventilation (MV), patient-ventilator interaction, weaning. / Development of software for continuous monitoring of critically ill patients on MV. Processing and storing digital signals from monitoring equipment or ventilators. / Software for interpretation, analysis and multimodal-multichannel physiological- diagnosed computerized interpretation of biomedical signals. / Design and application of a smart data display to help clinical decision making. / Early diagnosis and treatment of ventilator-associated pneumonia.
• Development of experimental models (animals and cell cultures) for the characterization of new mechanisms involved in acute lung injury (ALI) and prevention strategies.
• Development of new therapeutic strategies for ALI and ARDS management.
Pharmacological approach (systemic or inhaled) by administering anticoagulants, heparin, AT-III, thrombomodulin or immunomodulators in animal and cell culture models. / Cell therapy based on local
42
PROGRAMMES
Diffuse Respiratory Diseases Infectious Respiratory Diseases